Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: A 4-year experience

Liver International

Volumn 31, Issue 2, 2011, Pages 206-214

  Chen, Chien Hung ^a   Wang, Jing Houng ^a   Lu, Sheng Nan ^a   Hu, Tsung Hui ^a   Hung, Chao Hung ^a   Chang, Min Hui ^a   Changchien, Chi Sin ^a   Lee, Chuan Mo ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Adefovir dipivoxil; Cirrhosis; Hepatitis B virus; Lamivudine; YMDD mutant

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE SEQUENCE; DRUG SUBSTITUTION; FEMALE; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; TREATMENT DURATION; VIRUS GENOME;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; BASE SEQUENCE; CLONING, MOLECULAR; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHOSPHONIC ACIDS; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 78650770526     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02416.x     Document Type: Article

References (36)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-70.
3. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29 (Suppl. 1): 100-7.
4. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86: 1143-50.
5. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-3.
6. Lai CL, Ching CK, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25: 241-4.
7. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
8. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
9. Lee CM, Ong GY, Lu SN, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002; 37: 669-74.
10. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
11. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-73.
12. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-34.
13. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open label pilot study. Lancet 2001; 358: 718-23.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
15. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudineresistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-91.
16. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-95.
17. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.
18. Chen CH, Wang JH, Lee CM, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 2006; 11: 771-8.
19. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.
20. Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-61.
21. Mutimer D, Pillay D, Cook P, et al. Selection of multi-resistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000; 181: 713-6.
22. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy of chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-7.
23. Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat 2006; 13: 250-5.
24. Chen CH, Lee CM, Lu SN, et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol 2005; 43: 6000-6.
25. Chen CH, Lee CM, Lu SN, et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 2006; 44: 76-82.
26. Chen CH, Lee CM, Lu SN, et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004; 41: 454-61.
27. Mizokami M, Nakano T, Orito E, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999; 450: 66-71.
28. Cho YK, Cui SJ, Shin JW, Park NH, Song BC. Mutation in the basal core promoter in lamivudine-resistant patients with chronic hepatitis B is a predictor of viral breakthrough during sequential adefovir monotherapy. Hepatology 2008; 48: 957A.
29. Lampertico P, Viganó M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
30. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
31. Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88: 4186-90.
32. Tseng TC, Liu CJ, Wang CC, et al. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther 2009; 14: 203-10.
33. Vassiliadis T, Nikolaidis N, Giouleme O, et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Alim Pharmacol Ther 2005; 21: 531-7.
34. Reijnders JG, Leemans WF, Hansen BE, et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: viroloigic response can be assessed at 24 weeks. J Viral Hepat 2009; 16: 113-20.
35. Shin JW, Park NH, Jung SW, et al. Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther 2009; 14: 181-6.
36. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.